

Date: July 23, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Outcome of Board Meeting of the Company – Disclosure under Regulation 30, 33 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In compliance with Regulations 30, 33, and 47 read with para-A of Part A of Schedule III and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e. Wednesday, July 23, 2025 has inter-alia, approved the following:

1. Un-audited Financial Results

Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025 together with the Limited Review Report thereon;

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), the Company hereby confirms and declares that, M/s. Pankaj R. Shah and Associates, Chartered Accountants (Firm Registration No. 107361W), Statutory Auditors of the Company have issued their Limited Review Reports on the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2025.

The financial results along with the reports of the auditors of the company are enclosed herewith as **Annexure-A**.

Media Release in relation to the Un-audited Standalone and Consolidated financial results of the Company for the quarter ended June 30, 2025 is enclosed herewith as **Annexure B**.

2. Change in the Senior Management Personnel (“SMP”) of the Company

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended from time to time, we wish to inform you that the Board, on recommendation of the Nomination and Remuneration Committee, approved the following change in the Senior Management Personnel of the Company:

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

- Appointment and categorization of Mr. Jignesh Shashikant Desai, President-Finance as SMP of the Company with effect from July 23, 2025.

The details as required under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is given in the **Annexure-C**.

Kindly note that the meeting of Board of Directors of the Company commenced at 03:15 P.M. (IST) and concluded at 04:30 P.M. (IST).

This intimation and aforesaid information are also being uploaded on the Company's website at www.senorespharma.com.

You are requested to take the same on record.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Enclosures: As above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Pankaj R Shah & Associates

Chartered Accountants

CA. DR. Pankaj Shah B.Com., F.C.A., Ph. D. (Commerce)	CA. Chintan Shah B.Com., L.L.B., F.C.A.	CA. Nilesh Shah B.Com., L.L.B., F.C.A.	CA. Manali Shah B.Com., F.C.A.	CA. Sandip Gupta B.Com., F.C.A.
--	--	---	-----------------------------------	------------------------------------

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. URL : <http://www.prsca.in>

Independent Auditors Limited Review Report on the Quarter ended Unaudited Consolidated Financial Results of the Company pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, (the "Listing Regulations").

Review Report to,

The Board of Directors

Senores Pharmaceuticals Limited,

We have reviewed the consolidated statement of unaudited consolidated financial results of **Senores Pharmaceuticals Limited** (the "company") for the quarter ended on 30th June, 2025 (the "statement") including its subsidiary's share of net profit/(loss) after tax and total comprehensive income/loss, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").


The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

The statement includes the results of the following subsidiary;

1. Havix Group INC D/B/A Aavis Pharmaceuticals
2. Senores Pharmaceuticals INC
3. Ratnatris Pharmaceuticals Private Limited
4. 9488 Jackson Trail LLC (Step-down subsidiary)

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The accompanying statements includes unaudited interim financial results of 3 subsidiary and 1 Stepdown subsidiary included in the statement, whose unaudited interim financial results reflect total revenues Rs.130.6 Crores, total net profit after tax of Rs. 19.5 Crores and total comprehensive



income is Rs. 19.9 Crore for the quarter ended 30th June, 2025 respectively, as considered in the respective consolidated unaudited financial results. These unaudited interim financial results of this subsidiary have been reviewed by their auditors and have been approved and furnished to us by the management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on such unaudited interim financial results and information. Our conclusion is not modified in respect of this matter.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("Ind AS") as specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

1. The statement includes the results for the corresponding quarter ended 30th June - 2024 which have been prepared solely based on the information complied by the management and have not been subject to an audit or review and have been approved by the Board of Directors.
2. Tax Provisions and Deferred Tax have been determined as estimated by the management solely. our conclusion on the statement is not modified in respect of these matters.

For, Pankaj R Shah & Associates

Chartered Accountants

Registration No.107361W

N. R. Shah



CA Nilesh Shah

Partner

Membership No.107414

UDIN: *25107414BM91X8235*

Place :Ahmedabad

Date: *23/7/2025*

SENORES PHARMACEUTICALS LIMITED

(Formerly known as Senores Pharmaceuticals Private Limited)

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054
CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIALS RESULTS FOR THE QUARTER ENDED JUNE 30, 2025				
(Rs. in Crores except for share data)				
Sr No.	Particulars	Quarter Ended		Year Ended
		June 30, 2025	March 31, 2025	June 30, 2024
		Unaudited	Audited (Refer Note 12)	Unaudited (Refer Note 5)
1	Revenue from operations			
	Sales / Income from operations	130.30	104.87	79.50
	Other Operating Income	7.69	9.34	0.89
	Total Revenue from operations	137.99	114.21	80.39
2	Other income	3.36	11.77	0.48
3	Total Income (1+2)	141.35	125.98	80.87
4	Expenses			
	Cost of materials consumed	29.38	20.94	19.52
	Purchases of stock-in-trade	27.55	29.06	16.63
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	4.43	7.46	(1.53)
	Employee benefits expenses	21.65	14.63	12.03
	Finance costs	5.04	5.30	4.82
	Depreciation & Amortisation expenses	5.99	5.23	3.52
	Other expenses	20.81	22.68	12.43
	Total expenses	114.86	105.30	67.41
5	Profit before Tax (3-4)	26.49	20.68	13.46
6	Tax expense			
	Current tax	4.91	6.73	1.32
	Deferred tax	0.40	(4.02)	1.24
	Total Tax Expense	5.31	2.71	2.56
7	Net Profit after tax (5-6)	21.18	17.97	10.91
8	Other Comprehensive Income / (Loss)			
	A (i) Items that will not be reclassified subsequently to profit or loss	-	(0.27)	-
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	0.03	-
	B (i) Items that will be reclassified subsequently to profit or loss	0.47	0.13	(0.20)
	(ii) Income tax relating to items that will be reclassified to profit and loss	-	-	-
	Total Other Comprehensive Income / (Loss)	0.47	(0.12)	(0.20)
9	Total Comprehensive Income (7+8)	21.65	17.85	10.71
10	Profit for the period attributable to			
	Equity Holders of the Company	19.73	17.83	10.73
	Non Controlling Interests	1.45	0.14	0.18
	Other Comprehensive Income attributable to			
	Equity Holders of the Company	0.32	(0.28)	(0.15)
	Non Controlling Interests	0.15	0.16	(0.05)
	Total Comprehensive Income attributable to	20.05	17.56	10.57
	Equity Holders of the Company	1.60	0.29	0.14
	Non Controlling Interests			
11	Paid up Equity Share Capital (Face Value Rs 10 per share)			46.05
12	Other Equity			740.13
13	Earnings per share (Face Value Rs 10 per share)			
	(Not annualised for the quarter)			
	Basic	4.60	3.81	3.39
	Diluted	4.60	3.81	3.39

See accompanying notes to the financial results



SENORES PHARMACEUTICALS LIMITED

(Formerly known as Senores Pharmaceuticals Private Limited)

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad,
Gujarat, India, 380054

CIN:L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Notes to statement of unaudited consolidated financial results:

1. The above statement of unaudited consolidated financial results of Senores Pharmaceuticals Limited ("Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on July 23, 2025.
2. The above statement of consolidated unaudited financial results of Senores Pharmaceuticals Limited has been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
3. In accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the above statement of unaudited consolidated financial results have been reviewed by the Statutory Auditors of the Company for the quarter ended on June 30, 2025.
4. The unaudited reviewed results for the below mentioned Subsidiaries are consolidated in the above statement of consolidated Unaudited financial results of the Company.
 - i. Senores Pharmaceuticals Inc (wholly owned subsidiary)
 - ii. Havix Group Inc. (Subsidiary wef May 3rd, 2023)
 - iii. Ratnatris Pharmaceuticals Private Limited (Subsidiary wef December 14th, 2023)
 - iv. 9488 Jackson Trail LLC (Step-Down Subsidiary wef May 3rd, 2023)
5. The statement of unaudited consolidated financial results for the corresponding previous quarter ended June 30, 2024, are presented based on the information compiled by the management of the company in accordance with Ind AS 34 and have not been subjected to a review or audit by the statutory auditors. However, the management has prepared the results for the said period applying consistent accounting policies.
6. During the quarter ended on December 31, 2024, the Company had completed its Initial Public Offer (IPO) of 14,887,723 equity shares of face value of Rs 10 each at an issue price of Rs. 391 per share (including a share premium of Rs. 381 per share). The issue comprised of a fresh issue of 12,787,723 equity shares aggregating to Rs. 500 crores and offer for sale of 2,100,000 equity shares by selling shareholders aggregating to Rs. 82.11 crores, totaling Rs. 582.11 crores. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on December 30, 2024.



SENORES PHARMACEUTICALS LIMITED

(Formerly known as Senores Pharmaceuticals Private Limited)

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad,
Gujarat, India, 380054

CIN:L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

7. The Proceeds of IPO have been utilized upto June 30th, 2025 as per the below mentioned table:

(Rs in crores)

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized as on June 30, 2025	Total Amount Unutilized as on June 30, 2025	Remarks
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility	107.00	-	107.00	Out of the unutilized amount, Rs 114.00 crores parked as Fixed Deposit with HDFC Bank, Rs 140.45 crores parked as Fixed Deposit with ICICI Bank and balance Rs 4.56 crores held in HDFC bank account.
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company	73.48	73.10	0.38	
3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.22	20.20	0.02	
4	Funding the working capital requirements of our Company	43.26	37.73	5.53	
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	26.15	33.33	
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes	154.37	51.86	102.51	
7	Offer expenses	42.19	31.94	10.25	
	Total	500.00	240.99	259.01	



SENORES PHARMACEUTICALS LIMITED

(Formerly known as Senores Pharmaceuticals Private Limited)

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054


CIN:L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

8. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.
9. The Company is operating in a single segment i.e Pharmaceuticals. Hence, the above financial results are prepared on a single segment only.
10. Previous period figures have been regrouped and / or re-arranged wherever necessary to make their classification comparable with current period.
11. Other Income of Q4 and FY 24-25 includes other operating income of Rs 5.95 Cr and Rs 12.11 Cr respectively.
12. The consolidated audited financial results for the quarter ended on March 31, 2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year to date figures up to December 31, 2024 of the said financial year.
13. The full text of Senores Pharmaceuticals Limited's statement of unaudited consolidated financial results is available in the Investors section of our website at www.senorespharma.com and is also available on the websites of BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively.

Place: Ahmedabad

Date: July 23, 2025

For Senores Pharmaceuticals Limited



Swapnil Jatimbhai Shah
Managing Director
DIN:05259821



Pankaj R Shah & Associates

Chartered Accountants

CA. DR. Pankaj Shah
B.Com., F.C.A., Ph. D. (Commerce)

CA. Chintan Shah
B.Com., L.L.B., F.C.A.

CA. Nilesh Shah
B.Com., L.L.B., F.C.A.

CA. Manali Shah
B.Com., F.C.A.

CA. Sandip Gupta
B.Com., F.C.A.

7th Floor, Regency Plaza, Opp. Rahul Tower, Nr. Madhur Hall, Anandnagar Cross Road, Satellite, Ahmedabad-380015. India. Phone : +91 79 - 4603 1545, 4603 1546, 4032 1025. URL : <http://www.prsca.in>

Independent Auditors' Limited Review Report on Quarterly and unaudited Standalone Ind AS Financial Results of M/s Senores Pharmaceuticals Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,

The Board of Directors

Senores Pharmaceuticals Limited

We have reviewed the accompanying Statement of Standalone Ind AS Financial Results of Senores Pharmaceuticals Limited (the "Company"), for the quarter ended June 30, 2025 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" as prescribed under Section 133 of Companies Act, 2013, as amended read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular is the responsibility of the Company's Management and approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard ("Ind AS") as specified under Section 133 of Companies Act, 2013 as amended



read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular including the manner in which it is to be disclosed, or that it contains any material misstatement.

Emphasis of Matter

1. The statement includes the results for the corresponding quarter ended 30th June - 2024 which have been prepared solely based on the information complied by the management and have not been subject to an audit or review and have been approved by the Board of Directors.
2. Tax Provisions and Deferred Tax have been determined as estimated by the management solely.
our conclusion on the statement is not modified in the respect of these matters.

For Pankaj R Shah & Associates
Chartered Accountants
(Firm Regn.No.107361W)

N. R. Shah
CA Nilesh Shah
Partner

Membership No. 107414
UDIN : 25107414BMGIXW5514
Place: Ahmedabad
Date: 23-07-2025



SENORES PHARMACEUTICALS LIMITED

(Formerly known as Senores Pharmacueticals Private Limited)

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN: L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

STATEMENT OF UNAUDITED STANDALONE FINANCIALS RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(Rs. in Crores except for share data)

Sr No.	Particulars	Quarter Ended		Year Ended	
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		Unaudited	Audited (Refer Note 9)	Unaudited (Refer Note 3)	Audited
1	Revenue from operations				
	Sales / Income from operations	15.49	11.86	7.48	38.54
	Other Operating Income	4.33	-	-	-
	Total Revenue from operations	19.82	11.86	7.48	38.54
2	Other income	8.39	9.25	2.45	21.99
3	Total Income (1+2)	28.21	21.11	9.93	60.53
4	Expenses				
	Cost of materials consumed	1.40	2.81	0.96	7.26
	Purchases of stock-in-trade	2.34	7.46	1.29	14.67
	Changes in inventories of finished goods, work-in-progress and stock-in-trade	3.41	(3.54)	0.57	(4.10)
	Employee benefits expenses	6.91	4.45	3.95	18.25
	Finance costs	1.76	2.35	0.80	6.52
	Depreciation & Amortisation expenses	1.88	1.27	0.52	3.08
	Other expenses	6.92	3.41	1.49	9.74
	Total expenses	24.62	18.21	9.58	55.42
5	Profit before Tax (3-4)	3.59	2.89	0.35	5.11
6	Tax expense				
	Current tax	0.39	0.48	0.28	1.45
	Deferred tax	0.51	0.40	(0.23)	(0.03)
	Total Tax Expense	0.90	0.88	0.04	1.42
7	Net Profit after tax (5-6)	2.70	2.01	0.31	3.69
8	Other Comprehensive Income / (Loss)				
	A (i) Items that will not be reclassified subsequently to profit or loss	-	(0.25)	(0.06)	(0.29)
	(ii) Income tax relating to items that will not be reclassified to profit and loss	-	0.05	0.02	0.06
	B (i) Items that will be reclassified subsequently to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit and loss	-	-	-	-
	Total Other Comprehensive Income / (Loss)	-	(0.20)	(0.04)	(0.23)
9	Total Comprehensive Income (7+8)	2.70	1.81	0.27	3.47
10	Paid up Equity Share Capital (Face Value Rs 10 per share)				46.05
11	Other Equity				681.91
12	Earnings per share (Face Value Rs 10 per share) (Not annualised for the quarter)				
	Basic	0.59	0.39	0.09	1.02
	Diluted	0.59	0.39	0.09	1.02

See accompanying notes to the financial results



SENORES PHARMACEUTICALS LIMITED

(Formerly known as Senores Pharmaceuticals Private Limited)

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN:L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

Notes to statement of unaudited standalone financial results:

- 1 The above statement of unaudited standalone financial results of Senores Pharmaceuticals Limited ("Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on July 23, 2025. The above statement of unaudited standalone financial results have been reviewed by the Statutory Auditors of the Company for the quarter ended on June 30, 2025.
- 2 The above statement of unaudited standalone financial results of Senores Pharmaceuticals Limited has been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 (the "Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended.
- 3 The statement of unaudited financial financial results for the corresponding previous quarter ended June 30, 2024, are presented based on the information compiled by the management of the company in accordance with Ind AS 34 and have not been subjected to a review or audit by the statutory auditors. However, the management has prepared the results for the said period applying consistent accounting policies.
- 4 During the quarter ended on December 31, 2024, the Company had completed its Initial Public Offer (IPO) of 14,887,723 equity shares of face value of Rs 10 each at an issue price of Rs. 391 per share (including a share premium of Rs. 381 per share). The issue comprised of a fresh issue of 12,787,723 equity shares aggregating to Rs. 5,000 million and offer for sale of 2,100,000 equity shares by selling shareholders aggregating to Rs. 821.10 million, totaling to Rs. 5,821.10 million. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on December 30, 2024.
- 5 The Proceeds of IPO have been utilized till June 30th, 2025 as per the below mentioned table:

(Rs in Crores)

Sr. No	Item Head	Amount as proposed in the Offer Document	Amount utilized as on June 30, 2025	Total Amount Unutilized as on June 30, 2025	Remarks
1	Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility	107.00	-	107.00	Out of the unutilized amount, Rs 114.00 crores parked as Fixed Deposit with HDFC Bank, Rs 140.45 crores
2	Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company	73.48	73.10	0.38	



SENORES PHARMACEUTICALS LIMITED

(Formerly known as Senores Pharmaceuticals Private Limited)

Registered Office: 1101 to 1103, 11th floor, South Tower, ONE 42, Opposite Jayantilal Park, Ambali Bopal Road, Ahmedabad, Gujarat, India, 380054

CIN:L24290GJ2017PLC100263 | Website: www.senorespharma.com | Phone: +91-79-29999857 | E-mail: cs@senorespharma.com

3	Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiaries	20.22	20.20	0.02	parked as Fixed Deposit with ICICI Bank and balance Rs 4.56 crores held in HDFC bank account
4	Funding the working capital requirements of our Company	43.26	37.73	5.53	
5	Investment in our Subsidiaries, namely, Senores Pharma Inc. and Ratnatris Pharmaceuticals Pvt Ltd. to fund their working capital requirements	59.48	26.15	33.33	
6	Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes	154.37	51.86	102.51	
7	Offer expenses	42.19	31.94	10.25	
	Total	500.00	240.99	259.01	

6. EPS for the respective periods have been calculated based on the weighted average number of shares outstanding for the said periods.
7. The Company is operating in a single segment i.e Pharmaceuticals. Hence, the above financial results are prepared on a single segment only.
8. Previous period figures have been regrouped and / or re-arranged wherever necessary to make their classification comparable with current period.
9. The standalone audited financial results for the quarter ended March 31,2025 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited year-to-date figures up to December 31, 2024 of the said financial year
10. The full text of Senores Pharmaceuticals Limited's statement of Standalone Audited financial results is available in the Investors section of our website at www.senorespharma.com and is also available on the websites of BSE Limited and National Stock Exchange of India Limited at www.bseindia.com and www.nseindia.com respectively.

For Senores Pharmaceuticals Limited

Place: Ahmedabad

Date: July 23, 2025


Swapnil Jatibhai Shah
Managing Director
DIN:05259821




SENORES PHARMACEUTICALS LIMITED

Strong Financial & Operational Performance for Q1FY26

Ahmedabad, Gujarat, 23rd July 2025 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its un-audited Financial Result for the first Quarter of FY26 ended 30th June 2025.


Q1 FY26 CONSOLIDATED FINANCIAL HIGHLIGHTS




* Total Income includes Revenue from Operations & Other Operating Income

Q1 FY26 OPERATIONAL & FINANCIAL HIGHLIGHTS


Revenue Mix (%)




Regulated Markets



Emerging Markets



Others



- For Q1FY26, **Regulated Markets** Revenue stood at Rs 90 crs, **growing by 69% Y-o-Y**. EBIDTA Margin for Regulated Markets business stood at 35.5% in Q1 FY26.
- For Q1 FY26, **Emerging Markets** Revenue stood at Rs. 29 crs, **growing by 32% Y-o-Y**. EBIDTA Margin for Emerging Markets business stood at 6% in Q1 FY26.
- In the Regulated Markets the company currently has:
 - 24 Own commercial products
 - 70 Approved ANDA products
 - 57 Pipeline products with 37 CGT opportunity products
 - 27 CDMO/CMO commercial products
 - 53 CDMO/CMO pipeline products
- For the Emerging Markets the company currently has:
 - 308 Registered products
 - 719 products under Registration
 - Presence across more than 40 countries

Commenting on the results, **Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited** said,

“Continuing the momentum from last year, we have started FY26 well, with healthy performance across segments during the quarter.

We launched 2 own ANDA products in the Regulated Markets during the quarter. We also received the ANDA approval for 4 products during the quarter. We have a strong pipeline in place which we will launch over the next couple of years. Our moat lies in our ability to serve the government channel in addition to the retail channel in the US. This gives us considerable competitive advantage in the US market. A large part of our product pipeline has potential to cater to the government contracts. Our capability to manufacture and supply controlled substances in US is another differentiator for us.

Our CDMO / CMO segment is also scaling up as planned. We are adding new contracts and increasing the share of pocket from existing customers. The contracts in hand give us good visibility for the year ahead. With respect to the US tariff situation, we believe we are largely insulated with our entire formulation manufacturing happening locally in US.

In the Emerging Markets, our changing product portfolio and go-to-market strategies are resulting in improved profitability.

Our Branded Generics segment is witnessing significant uptick in momentum. On the back of increasing field force, our monthly revenue run rate has more than doubled versus last year. We expect to be a pan-India player by the end of FY26.

We are also pleased to report positive Operating Cash Flow of Rs 11 crores for Q1FY26. We expect to sustain and build on the cash flow trajectory going forward.

Our business is undergoing a structural advancement which will provide better market visibility and support the growth momentum for us over the medium term to longer term. We will continue to drive the business on three key pillars – (i) Expansion of the ANDA Portfolio in Regulated Markets; (ii) Steady Scale-up of the CDMO/CMO Segment in Regulated Markets; and (iii) Portfolio Expansion and Profitability Improvement in Emerging Markets”

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 24 ANDA and 27 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with 308 registered products and 719 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact



Company : SENORES PHARMACEUTICALS LIMITED

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

SGA Strategic Growth Advisors

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899

Annexure C

Details with respect to changes in Senior Management Personnel ("SMP") under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024:

Sr. No	Particulars	Details
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Mr. Jignesh Shashikant Desai, President-Finance categorized as SMP of the Company with effect from July 23, 2025.
2.	Date of appointment/re-appointment/cessation (as applicable) and term of appointment	Effective from July 23, 2025 Terms and conditions as mentioned in the letter of appointment.
3	Brief Profile (in case of appointment)	Mr. Jignesh Shashikant Desai is a seasoned professional with over 30 years of experience in business finance, accounting, and procurement. He has played a strategic role in driving financial discipline, cost efficiency, and operational performance across the organization. His expertise spans in budgeting, costing, regulatory compliance and business planning. Before joining the Company, he undertook leadership roles at Cadila Pharmaceuticals, Zydus Cadila, Gokul Refoil and Solvents Limited and Ashima Denim. Being qualified Cost & Management Accountant and ICAI member, he will play a key role in driving financial strategy and operational efficiency at Senores.
4.	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263